Le Lézard
Classified in: Ebola virus, Health, Science and technology, Covid-19 virus

Middle East and Africa In-Vitro Diagnostics (IVD) Market Research Report 2022 - ResearchAndMarkets.com


The "In Vitro Diagnostics (IVD) in the Middle East and Africa" report has been added to ResearchAndMarkets.com's offering.

There has been an increasing standard of living in the Middle East and Africa due to higher national income. This has contributed to a higher incidence of heart disease - high blood pressure, high cholesterol and high blood sugar.

In fact, the Middle East/Africa region is one of the higher areas for heart disease which has prompted more individuals being admitted to the hospital. This has caused an uptick in the demand for diagnostic testing devices and medical devices.

Scope

The Middle East, Africa market for in vitro diagnostics is provided in U.S. dollars for the years 2021 - 2026.

The report covers six segments of the IVD market in the Middle East:

This report provides an overview of developments in the in vitro diagnostics industry in the Middle East and Africa with focus on the following countries

Key Topics Covered:

Chapter 1: Executive Summary

Chapter 2: Middle East and Africa: Regional Overview

Chapter 3: Egypt IVD Market

Chapter 4: Iran IVD Market

Chapter 5: Iraq IVD Market

Chapter 6: Israel IVD Market

Chapter 7: Jordan IVD Market

Chapter 8: Saudi Arabia IVD Market

Chapter 9: South Africa IVD Market

Chapter 10: Turkey IVD Market

Chapter 11: United Arab Emirates (UAE) IVD Market

Chapter 12: Total Mideast & Africa IVD Market

For more information about this report visit https://www.researchandmarkets.com/r/p0qcix


These press releases may also interest you

at 22:00
Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its...

at 20:14
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 19:30
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

at 18:00
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...



News published on and distributed by: